Trial Search Results

Study of SRP-4045 and SRP-4053 in DMD Patients

The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Sarepta Therapeutics


  • Drug: SRP-4045
  • Drug: SRP-4053
  • Drug: Placebo


Phase 3


Inclusion Criteria:

   - Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53

   - Stable dose of oral corticosteroids for at least 24 weeks

   - Intact right and left biceps or 2 alternative upper muscle groups

   - Mean 6MWT greater than or equal 300 meters and less than or equal to 450 meters

   - Stable pulmonary and cardiac function: forced vital capacity (FVC) equal to or greater
   than 50% predicted and left ventricular ejection fraction (LVEF) greater than 50%

Exclusion Criteria:

   - Previous treatment with SMT C1100 (BMN-195) at any time

   - Treatment with gene therapy at any time

   - Previous treatment with PRO045 or PRO053 within 24 weeks prior to Week 1

   - Current or previous treatment with any other experimental treatment (other than
   deflazacort) within 12 weeks prior to Week 1

   - Participation in any other DMD interventional clinical study within 12 weeks prior to
   Week 1

   - Major surgery within 3 months prior to Week 1

   - Presence of other clinically significant illness

   - Major change in physical therapy regimen within 3 months prior to Week 1

Ages Eligible for Study

7 Years - 13 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305